Nls pharmaceutics to present at the 35th annual roth conference

Zurich, switzerland / accesswire / march 1, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced alex zwyer, ceo, will be presenting at the 35th annual roth conference.

NLSP Ratings Summary

NLSP Quant Ranking